APA (7th ed.) Citation

Zhu, J., Nowakowski, G., Zhang, Q., Brody, J., Sun, X., Maly, J., . . . Smith, S. D. (2019). Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1. Blood, 134(Supplement_1), 5330. https://doi.org/10.1182/blood-2019-124930

Chicago Style (17th ed.) Citation

Zhu, Jun, et al. "Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1." Blood 134, no. Supplement_1 (2019): 5330. https://doi.org/10.1182/blood-2019-124930.

MLA (9th ed.) Citation

Zhu, Jun, et al. "Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1." Blood, vol. 134, no. Supplement_1, 2019, p. 5330, https://doi.org/10.1182/blood-2019-124930.